Chinese General Practice ›› 2022, Vol. 25 ›› Issue (36): 4502-4508.DOI: 10.12114/j.issn.1007-9572.2022.0446
Special Issue: 高血压最新文章合集; 肥胖最新文章合集
• Article • Previous Articles Next Articles
Received:
2022-04-20
Revised:
2022-07-10
Published:
2022-12-20
Online:
2022-09-08
Contact:
GE Xuhua
About author:
通讯作者:
葛许华
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0446
指标 | LVH(-)组(n=133) | LVH(+)组(n=235) | 检验统计量值 | P值 | |
---|---|---|---|---|---|
性别〔n(%)〕 | 11.058a | 0.001 | |||
男 | 101(75.9) | 138(58.7) | |||
女 | 32(24.1) | 97(41.3) | |||
年龄〔M(P25,P75),岁〕 | 51.0(35.5,64.0) | 57.0(48.0,68.0) | -4.375b | <0.001 | |
BMI〔M(P25,P75),kg/m2〕 | 27.7(25.9,30.7) | 27.3(25.6,29.9) | -1.151b | 0.250 | |
BSA(m2) | 1.9±0.2 | 1.8±0.2 | 4.725c | <0.001 | |
SBP〔M(P25,P75),mm Hg〕 | 140.0(126.0,154.5) | 155.0(138.0,170.0) | -5.176b | <0.001 | |
DBP〔M(P25,P75),mm Hg〕 | 85.0(77.0,92.0) | 88.0(79.0,100.0) | -2.530b | 0.011 | |
吸烟史〔n(%)〕 | 34(25.6) | 51(21.7) | 0.713a | 0.398 | |
饮酒史〔n(%)〕 | 18(13.5) | 37(15.7) | 0.327a | 0.568 | |
高血压家族史〔n(%)〕 | 4(3.0) | 9(3.8) | 0.014d | 0.907 | |
高血压病程〔n(%)〕 | 1.191a | 0.551 | |||
<10年 | 96(72.2) | 157(66.8) | |||
10~20年 | 25(18.8) | 51(21.7) | |||
>20年 | 12(9.0) | 27(11.5) | |||
糖尿病史〔n(%)〕 | 52(39.1) | 83(35.3) | 0.522a | 0.470 | |
卒中史〔n(%)〕 | 21(15.8) | 32(13.6) | 0.325a | 0.569 | |
冠心病史〔n(%)〕 | 22(16.5) | 42(17.9) | 0.105a | 0.746 | |
血脂异常〔n(%)〕 | 69(51.9) | 110(46.8) | 0.874a | 0.350 | |
用药情况〔n(%)〕 | |||||
ACEI | 26(19.6) | 60(25.5) | 1.698a | 0.193 | |
ARB | 48(36.1) | 76(32.3) | 0.535a | 0.465 | |
CCB | 86(64.7) | 162(68.9) | 0.706a | 0.401 | |
β-受体阻滞剂 | 20(15.0) | 61(26.0) | 5.900a | 0.015 | |
利尿剂 | 14(10.5) | 40(17.0) | 2.862a | 0.091 | |
血压控制情况〔n(%)〕 | 7.686a | 0.021 | |||
差 | 31(23.3) | 86(36.6) | |||
一般 | 29(21.8) | 50(21.3) | |||
尚可 | 73(54.9) | 99(42.1) |
Table 1 Comparison of baseline data between LVH(-)and LVH(+) groups
指标 | LVH(-)组(n=133) | LVH(+)组(n=235) | 检验统计量值 | P值 | |
---|---|---|---|---|---|
性别〔n(%)〕 | 11.058a | 0.001 | |||
男 | 101(75.9) | 138(58.7) | |||
女 | 32(24.1) | 97(41.3) | |||
年龄〔M(P25,P75),岁〕 | 51.0(35.5,64.0) | 57.0(48.0,68.0) | -4.375b | <0.001 | |
BMI〔M(P25,P75),kg/m2〕 | 27.7(25.9,30.7) | 27.3(25.6,29.9) | -1.151b | 0.250 | |
BSA(m2) | 1.9±0.2 | 1.8±0.2 | 4.725c | <0.001 | |
SBP〔M(P25,P75),mm Hg〕 | 140.0(126.0,154.5) | 155.0(138.0,170.0) | -5.176b | <0.001 | |
DBP〔M(P25,P75),mm Hg〕 | 85.0(77.0,92.0) | 88.0(79.0,100.0) | -2.530b | 0.011 | |
吸烟史〔n(%)〕 | 34(25.6) | 51(21.7) | 0.713a | 0.398 | |
饮酒史〔n(%)〕 | 18(13.5) | 37(15.7) | 0.327a | 0.568 | |
高血压家族史〔n(%)〕 | 4(3.0) | 9(3.8) | 0.014d | 0.907 | |
高血压病程〔n(%)〕 | 1.191a | 0.551 | |||
<10年 | 96(72.2) | 157(66.8) | |||
10~20年 | 25(18.8) | 51(21.7) | |||
>20年 | 12(9.0) | 27(11.5) | |||
糖尿病史〔n(%)〕 | 52(39.1) | 83(35.3) | 0.522a | 0.470 | |
卒中史〔n(%)〕 | 21(15.8) | 32(13.6) | 0.325a | 0.569 | |
冠心病史〔n(%)〕 | 22(16.5) | 42(17.9) | 0.105a | 0.746 | |
血脂异常〔n(%)〕 | 69(51.9) | 110(46.8) | 0.874a | 0.350 | |
用药情况〔n(%)〕 | |||||
ACEI | 26(19.6) | 60(25.5) | 1.698a | 0.193 | |
ARB | 48(36.1) | 76(32.3) | 0.535a | 0.465 | |
CCB | 86(64.7) | 162(68.9) | 0.706a | 0.401 | |
β-受体阻滞剂 | 20(15.0) | 61(26.0) | 5.900a | 0.015 | |
利尿剂 | 14(10.5) | 40(17.0) | 2.862a | 0.091 | |
血压控制情况〔n(%)〕 | 7.686a | 0.021 | |||
差 | 31(23.3) | 86(36.6) | |||
一般 | 29(21.8) | 50(21.3) | |||
尚可 | 73(54.9) | 99(42.1) |
指标 | LVH(-)组(n=133) | LVH(+)组(n=235) | Z值 | P值 |
---|---|---|---|---|
IVST(mm) | 11.0(9.0,11.5) | 12.0(11.0,13.0) | -10.783 | <0.001 |
LVPWT(mm) | 10.0(8.0,11.0) | 12.0(11.0,13.0) | -10.987 | <0.001 |
LVM(g) | 162.0(131.0,197.0) | 256.0(220.0,302.0) | -13.657 | <0.001 |
LVMI(g/m2) | 87.0(64.5,103.0) | 138.0(123.0,158.0) | -15.337 | <0.001 |
LVEF(%) | 65.0(62.0,67.5) | 63.0(60.0,66.0) | -3.237 | 0.001 |
平均RR间期(ms) | 821.0(709.5,916.0) | 821.0(705.0,937.0) | -0.177 | 0.860 |
HR(次/min) | 73.0(65.5,84.5) | 73.0(64.0,85.0) | -0.177 | 0.860 |
P波时限〔M(P25,P75),ms〕 | 96.0(88.0,106.0) | 96.0(88.0,104.0) | -0.755 | 0.450 |
PR间期(ms) | 160.0(148.0,178.0) | 162.0(148.0,180.0) | -0.590 | 0.555 |
QRSd(ms) | 94.0(86.0,100.0) | 98.0(90.0,106.0) | -3.603 | <0.001 |
QTc(ms) | 430.0(408.0,448.0) | 444.0(420.0,464.0) | -4.274 | <0.001 |
Sokolow-Lyon电压(mV) | 2.1(1.7,2.7) | 2.8(1.9,3.9) | -5.533 | <0.001 |
Cornell电压(mV) | 1.5(1.0,2.1) | 2.1(1.5,2.7) | -6.225 | <0.001 |
Peguero Lo-Presti电压(mV) | 2.1(1.5,2.7) | 2.7(1.9,3.9) | -5.165 | <0.001 |
Cornell乘积(mV·ms) | 1 845.0(1 231.0,3 830.4) | 3 643.2(2 224.8,6 873.6) | -7.076 | <0.001 |
Table 2 Comparison of UCG and ECG-related indices between LVH(-)and LVH(+) groups
指标 | LVH(-)组(n=133) | LVH(+)组(n=235) | Z值 | P值 |
---|---|---|---|---|
IVST(mm) | 11.0(9.0,11.5) | 12.0(11.0,13.0) | -10.783 | <0.001 |
LVPWT(mm) | 10.0(8.0,11.0) | 12.0(11.0,13.0) | -10.987 | <0.001 |
LVM(g) | 162.0(131.0,197.0) | 256.0(220.0,302.0) | -13.657 | <0.001 |
LVMI(g/m2) | 87.0(64.5,103.0) | 138.0(123.0,158.0) | -15.337 | <0.001 |
LVEF(%) | 65.0(62.0,67.5) | 63.0(60.0,66.0) | -3.237 | 0.001 |
平均RR间期(ms) | 821.0(709.5,916.0) | 821.0(705.0,937.0) | -0.177 | 0.860 |
HR(次/min) | 73.0(65.5,84.5) | 73.0(64.0,85.0) | -0.177 | 0.860 |
P波时限〔M(P25,P75),ms〕 | 96.0(88.0,106.0) | 96.0(88.0,104.0) | -0.755 | 0.450 |
PR间期(ms) | 160.0(148.0,178.0) | 162.0(148.0,180.0) | -0.590 | 0.555 |
QRSd(ms) | 94.0(86.0,100.0) | 98.0(90.0,106.0) | -3.603 | <0.001 |
QTc(ms) | 430.0(408.0,448.0) | 444.0(420.0,464.0) | -4.274 | <0.001 |
Sokolow-Lyon电压(mV) | 2.1(1.7,2.7) | 2.8(1.9,3.9) | -5.533 | <0.001 |
Cornell电压(mV) | 1.5(1.0,2.1) | 2.1(1.5,2.7) | -6.225 | <0.001 |
Peguero Lo-Presti电压(mV) | 2.1(1.5,2.7) | 2.7(1.9,3.9) | -5.165 | <0.001 |
Cornell乘积(mV·ms) | 1 845.0(1 231.0,3 830.4) | 3 643.2(2 224.8,6 873.6) | -7.076 | <0.001 |
自变量 | B | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
性别 | -1.549 | 0.978 | 2.512 | 0.113 | 0.212 | (0.031,1.443) |
年龄 | 0.045 | 0.011 | 17.361 | <0.001 | 1.046 | (1.024,1.069) |
BSA | -0.736 | 0.965 | 0.582 | 0.446 | 0.479 | (0.072,3.176) |
SBP | 0.009 | 0.009 | 0.977 | 0.323 | 1.009 | (0.992,1.026) |
DBP | 0.022 | 0.013 | 2.737 | 0.098 | 1.022 | (0.996,1.049) |
β-受体阻滞剂 | -0.244 | 0.358 | 0.464 | 0.496 | 0.784 | (0.389,1.580) |
QRSd | 0.036 | 0.035 | 1.057 | 0.304 | 1.037 | (0.968,1.111) |
QTc | 0.004 | 0.004 | 0.726 | 0.394 | 1.004 | (0.995,1.012) |
Sokolow-Lyon电压 | 0.584 | 0.162 | 12.958 | <0.001 | 1.793 | (1.305,2.463) |
Cornell电压 | 0.693 | 1.502 | 0.213 | 0.645 | 1.999 | (0.105,37.975) |
Peguero Lo-Presti电压 | -0.351 | 0.257 | 1.876 | 0.171 | 0.704 | (0.426,1.164) |
Cornell乘积 | 0.001 | 0.002 | 0.022 | 0.881 | 1.001 | (0.997,1.003) |
常量 | -9.825 | 3.471 | 8.011 | 0.005 |
Table 3 Logistic regression analysis of the factors associated with left ventricular hypertrophy in overweight and obese patients with hypertension
自变量 | B | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
性别 | -1.549 | 0.978 | 2.512 | 0.113 | 0.212 | (0.031,1.443) |
年龄 | 0.045 | 0.011 | 17.361 | <0.001 | 1.046 | (1.024,1.069) |
BSA | -0.736 | 0.965 | 0.582 | 0.446 | 0.479 | (0.072,3.176) |
SBP | 0.009 | 0.009 | 0.977 | 0.323 | 1.009 | (0.992,1.026) |
DBP | 0.022 | 0.013 | 2.737 | 0.098 | 1.022 | (0.996,1.049) |
β-受体阻滞剂 | -0.244 | 0.358 | 0.464 | 0.496 | 0.784 | (0.389,1.580) |
QRSd | 0.036 | 0.035 | 1.057 | 0.304 | 1.037 | (0.968,1.111) |
QTc | 0.004 | 0.004 | 0.726 | 0.394 | 1.004 | (0.995,1.012) |
Sokolow-Lyon电压 | 0.584 | 0.162 | 12.958 | <0.001 | 1.793 | (1.305,2.463) |
Cornell电压 | 0.693 | 1.502 | 0.213 | 0.645 | 1.999 | (0.105,37.975) |
Peguero Lo-Presti电压 | -0.351 | 0.257 | 1.876 | 0.171 | 0.704 | (0.426,1.164) |
Cornell乘积 | 0.001 | 0.002 | 0.022 | 0.881 | 1.001 | (0.997,1.003) |
常量 | -9.825 | 3.471 | 8.011 | 0.005 |
指标 | 截断值 | 灵敏度 | 特异度 | AUC | 约登指数 | P值 |
---|---|---|---|---|---|---|
Sokolow-Lyon电压 | 2.685 | 0.566 | 0.752 | 0.674 | 0.318 | <0.001 |
Cornell电压 | 1.615 | 0.706 | 0.602 | 0.695 | 0.308 | <0.001 |
Peguero Lo-Presti电压 | 2.555 | 0.545 | 0.729 | 0.662 | 0.274 | <0.001 |
Cornell乘积 | 2240.300 | 0.749 | 0.609 | 0.722 | 0.358 | <0.001 |
联合诊断模型 | 0.735 | 0.681 | 0.872 | 0.846 | 0.553 | <0.001 |
Table 4 Diagnostic efficacies of ECG-related indices and combined diagnostic model for left ventricular hypertrophy in overweight and obese patients with hypertension
指标 | 截断值 | 灵敏度 | 特异度 | AUC | 约登指数 | P值 |
---|---|---|---|---|---|---|
Sokolow-Lyon电压 | 2.685 | 0.566 | 0.752 | 0.674 | 0.318 | <0.001 |
Cornell电压 | 1.615 | 0.706 | 0.602 | 0.695 | 0.308 | <0.001 |
Peguero Lo-Presti电压 | 2.555 | 0.545 | 0.729 | 0.662 | 0.274 | <0.001 |
Cornell乘积 | 2240.300 | 0.749 | 0.609 | 0.722 | 0.358 | <0.001 |
联合诊断模型 | 0.735 | 0.681 | 0.872 | 0.846 | 0.553 | <0.001 |
Figure 2 ROC curves of ECG diagnostic criteria and combined diagnostic model for left ventricular hypertrophy in overweight and obese patients with hypertension
[1] |
孙宁玲,
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. 肥胖症基层诊疗指南(2019年)[J].中华全科医师杂志,2020,19(2):95-101. DOI:10.3760/cma.j.issn.1671-7368.2020.02.015.
|
[7] |
郑亮,吴宏,钱定广,等. 上海市高行老年社区人群动脉硬化性心血管疾病患病率的现况调查与危险因素分析[J]. 中国循证心血管医学杂志,2016,8(6):680-682,690. DOI:10.3969/j.issn.1674-4055.2016.06.10.
|
[8] |
中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56. DOI:10.3969/j.issn.1007-5410.2019.01.002.
|
[9] |
|
[10] | |
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
《中国高血压防治指南》修订委员会. 中国高血压防治指南2018年修订版[J]. 心脑血管病防治,2019,19(1):1-44. DOI:10.3969/j.issn.1009-816X.2019.01.001.
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[1] | ZHANG Shuai, LI Qin, LI Dongfeng, XIAO Jinping, LI Yunpeng. A Prospective Cohort Study of Solid Fuels Use and Risk of Hypertension in Chinese Older Adults [J]. Chinese General Practice, 2023, 26(32): 4001-4006. |
[2] | LI Jixin, QIU Linjie, REN Yan, WANG Wenru, LI Meijie, ZHANG Jin. The Correlation of Dietary Inflammatory Index with Overweight, Obesity and Abdominal Obesity: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4089-4097. |
[3] | HONG Yuchun, WU Hua, DU Yishan, LI Shuran, SUN Wenmin, YE Mingyu, ZHANG Yongjian, LI Yang. Development of General Practice Diagnostic Terminology and Coding and Empirical Study on Its Application [J]. Chinese General Practice, 2023, 26(31): 3896-3901. |
[4] | PAN Yaojia, WANG Weiqiang, YI Weizhuo, GAO Bing, FU Fanglin, HAN Zheng, SUN Meng, DONG Yaqin, GU Huaicong. Relationship between Triglyceride-glucose Index and Risk of Cardiovascular Diseases in Middle-aged Obese Residents of Different Genders [J]. Chinese General Practice, 2023, 26(29): 3628-3635. |
[5] | XIAO Liqi, YANG Li, CUI Saixian, ZHANG Yayuan, WANG Yulu, HE Yan. Advances in the Association of High Salt-induced Gut Microbiota Disturbances with Salt-sensitive Blood Pressure [J]. Chinese General Practice, 2023, 26(29): 3704-3709. |
[6] | WANG Qianqian, WANG Xiaohang, ZHOU Xiaoying, QIU Shanhu, SUN Zilin. Exercise is the Foundation of Weight Loss [J]. Chinese General Practice, 2023, 26(28): 3471-3476. |
[7] | JIANG Qiuhui, LI Xuejun. Exercise is Not the Foundation of Weight Loss [J]. Chinese General Practice, 2023, 26(28): 3477-3481. |
[8] | CHENG Xiaoran, ZHANG Xiaotian, LI Mingyue, CHENG Haozhe, TANG Haoqing, ZHENG Huixian, ZHANG Baisong, LIU Xiaoyun. Impact of Chronic Diseases Follow-up on Health Behaviors and Blood Pressure/Glucose Control of Patients with Hypertension and Diabetes in the Context of Treatment-prevention Integration [J]. Chinese General Practice, 2023, 26(28): 3482-3488. |
[9] | CHEN Jing, ZOU Tao, ZHAO Danqing, XIAO Ziwen, WU Xianqing, Chinese Medical Association Psychosomatic Medicine Branch Perinatal Mental Disorders Collaborative Group. Expert Consensus on Screening, Diagnosis and Treatment of Perinatal Mental Disorders [J]. Chinese General Practice, 2023, 26(28): 3463-3470. |
[10] | BIAN Lili, LI Xiaoxiao, DU Xueping, DAI Qinfang, WU Lin, SONG Beibei. Risk Stratification of Atherosclerotic Cardiovascular Disease and Lipid Goal Attainment in Hypertensive Patients Registered in Community [J]. Chinese General Practice, 2023, 26(27): 3388-3391. |
[11] | YIN Zhaoxia, KONG Chongyu, ZOU Xianhui, LI Chuang, HUANG Yin, FENG Yang, WANG Yunfei, GONG Weijie. Traditional Chinese Medicine Disease Spectrum Analysis in Outpatient Clinics of Contracted Residents by Family Doctors in Shenzhen Community Health Service Centers [J]. Chinese General Practice, 2023, 26(25): 3112-3117. |
[12] | ZHANG Li, ZHENG Wei, WANG Jia, YUAN Xianxian, HAN Weiling, HUANG Junhua, TIAN Zhihong, LI Guanghui. Comparison of Gestational Weight Gain and Pregnancy Outcomes in Chinese Women with Singleton Pregnancy Using Standard of Recommendation for Weight Gain during Pregnancy Period and Guidelines by the Institute of Medicine [J]. Chinese General Practice, 2023, 26(24): 2959-2967. |
[13] | YIN Cong, DIAO He, SHENG Wei, CAO Yan, BAI Wenpei. Influence of Daily Self-weighing Supported by Online Supervision on Body Composition and Emotions in Overweight/Obese Women with Anxiety and Depression [J]. Chinese General Practice, 2023, 26(24): 2992-2996. |
[14] | ZHAO Wei, TANG Rongjie, YANG Shanshan, YANG Fang, SUN Feng, LIAN Qiufang. The Role and Molecules Mechanism of Klotho in Renal Injury in Salt-sensitive Hypertension [J]. Chinese General Practice, 2023, 26(24): 3042-3049. |
[15] | ZHANG Yunxu, WANG Tingting, WEI Junling, XING Yanyun, SU Li. A Newly Discovered Disease Affecting Women's Physical and Mental Health: Research Status and Expert Consensus Interpretation of Persistent Genital Arousal Disorder [J]. Chinese General Practice, 2023, 26(23): 2830-2835. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||